Anatomic Pathology Market (By Product and Service: Consumables [Reagents & Antibodies, Probes & Kits, Others], Instruments [Tissue processors, Automatic Stainers, Microtomes & Cryostat, Others], Services; By Application: Drug Discovery & Development, Disease Diagnosis, Others; By End-use: Hospitals, Diagnostic Laboratories, Research Laboratories, Others) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Published | Pages : 190


According to Acumen Research and Consulting, the global Anatomic Pathology market is forecasted to grow at striking CAGR around 6% over the forecast time frame and reach around US$ 24 billion by 2026.

The specialty of Anatomic Pathology is a medical science speciality linked to the diagnosis of different tissues and organ, using microscopic, macroscopic, immunological, biochemical or molecular exams. Operational pathology has unbelievably progressed from the primitive autopsy technique to a modernized approach over many years. It also focuses on diagnostic cancer and oncological forecasts, which help in decision-making and act as a guide in decision-making. The worldwide anatomical pathological market is pushing rapid growth of cancer, such as breast cancer, pulmonary cancer and colorectal cancer.

The report provides analysis of global Anatomic Pathology market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.

Market Insights

The increase in biomarker's clinical use allows pathologists to determine molecular pathogenesis of diseases, leading to better results for patients. The market is driven by growing dependence on biomarker pathology exams and processes for exploration of prevalent malignancy and tumorigenesis. Advanced pathology devices such as staining machines, gross imaging, and digital microscopes are ready for a significant improvement in anatomical pathology. In comparison to standard technologies, digital imaging solutions deliver specificity and accuracy advantages that in turn enhance service uptake in the global marketplace. Companies are continuously developing and improving their design and usability of sophisticated pathological equipment. In order to avoid difficulties related to the management of diseases, several partnership and agreement projects have also been undertaken among important businesses to introduce an efficient portfolio. For example, Sakura Finetek USA worked in October 2018 to develop the level of automation of its anatomy pathology labs through a partnership with Laboratory and Henry Ford Health Systems Pathology. The integration of automation in laboratories optimizes workflows for anatomical pathologies by reducing mistakes and turnaround time and provides high efficiency.

In order to raise knowledge about the technology and legal problems prevailing in anatomy, the considerable number of public pathology training programmes. In addition, these training modules emphasize training students' theoretical understanding, thus tackling the market challenge for specialists.

Product and Services Insights

For anatomic pathology procedures, a significant amount of reagents and kits, anticorps and probes are on the market. The main share of the revenue-generating segment is liable for the availability of a broad spectrum of products combined with a high consumables consumption in the study results. On the other side, the market members are anticipating continuing technological advances and concentrated attempts to deliver enhanced-designed anatomical devices for income development in their instrument sector. In September of 2018, Sakura Finetek launched the SRM 300 LT manual micro-tome, a fresh feature that allows paraffin embedded tissue samples to be viewed more simply for rapid visualization of transluent biopsies, incorporated into 4-color LED-backlit Precision Chuck. This item offers a fresh function.

Application Stance

The protocols of anatomical pathology give scientists the chance to investigate the etiology of diseases and related results. Thus the biggest share of revenues on the anatomical pathology market was in 2018 for the widespread implementation of disease diagnosis.

This workflow helps to detect a tumor at the point of inflammatory and multiplying stromal cells, minimizing tumor eradication expenses. Furthermore, manufacturers ' growing focus on introducing innovative and new diagnostic methods is accelerating segment development. The discovery and growth of drugs is expected to develop profitably over the forecast era. Pathologist's tissue assessment provides pharmaceutical manufacturers with a wealth of data during pre-clinical studies. In toxicology evaluation the adverse effects of candidate drugs play a crucial role in anatomical pathology.

End Use Stance

Due to the elevated hospitalization rates among cancer patients, together with a significant amount of frequent hospital readmissions in 2018, the hospitals dominated the industry in terms of revenues. In addition, the existence of well-developed infrastructure and well-trained personnel in hospital laboratories is stimulating the growth of the hospital segment. In addition, the segment is anticipated to benefit from growing numbers of government and private projects to support advanced care technologies. In the diagnostic laboratory segment, sophisticated test methods and equipment emerged that resulted in profitable growth possibilities. Similarly, the development of the study laboratories has been stimulated by a big amount of clinical trials through numerous continuing initiatives. Research laboratories provide fast and thorough data on the operation of ill tissues, with the general aim of reaching a high level of patient satisfaction.

Regional Stance

Due to significant players and supporting public projects related to training for pathological programs, North America accounted for the highest income share in 2018. The increased application, due to favourable reimbursement policies in the US, of the tissue-diagnostic associated processes in malignancy screening facilitates regional market growth. The growing demand for sophisticated imaging, the growth of enhanced care centres for patients and a number of pathology labs franchising Asia-Pacific presence fuels. In addition, there is a presence of government organizations, such as the Chinese Medical Association's pathology branch in China, to support pathology initiatives.

Market Segmentation

Global Anatomic Pathology Market, By Product and Service

  • Consumables
    • Reagents & Antibodies
    • Probes & Kits
    • Others
  • Instruments
    • Tissue processors
    • Automatic Stainers
    • Microtomes & Cryostat
    • Others
  • Services

Global Anatomic Pathology Market, By Application

  • Drug Discovery & Development
  • Disease Diagnosis
  • Others

Global Anatomic Pathology Market, By End-use

  • Hospitals
  • Diagnostic Laboratories
  • Research Laboratories
  • Others

Global Anatomic Pathology Market, By Geography

  • North America.
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa (MEA)

The market research study on “Anatomic Pathology Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Anatomic Pathology market segments with market dynamics and their impact. The report also covers basic technology development policies.

It offers an assessment of the recent industry trends for each sub-segment between 2015 and 2026, and anticipates income development at worldwide, regional and nation levels. For this research, ARC segmented the worldwide Anatomic Pathology market report on the grounds various segments.

Key Players & Strategies

Some of the key players are Laboratory Corporation of America Holdings; Thermo Fisher Scientific, Inc.; Sakura Finetek USA, Inc.Cardinal Health, Inc.; Agilent Technologies, Inc.; F. Hoffmann-La Roche AG; Quest Diagnostics Incorporated; BioGenex; NeoGenomics Laboratories, Inc.; and Bio SB.

These main players implement various approaches in order to retain their important market share during the forecast period. Collaborative development, corporate development and product development are the strategies introduced.

For instance, in June 2018, Agilent Technologies introduced a range of probes, such as MALT1, MYC, BCL6, BCL2, CCND1, IGH, IGH / BCL2, IGH / MYC, and IGH /CCND1, for in situ hybridization. The launch of these products has improved the portfolio of the company and thus reinforced its place in the industry.

Cart Summary